Kelvin Wang is the Managing Partner and General Manager of Huaige Capital, fully leading its general operation.

Kelvin has over 20 years of working experience in investment banking and private equity investment. He led investments in KDL(603987.SH), Warom Technology(603855.SH) and KDL Medical(01501.HK) and made critical contribution to their IPOs. Kelvin currently sits on the board of KDL Medical(01501.HK).

Leo Ding is a Partner of Huaige Capital and leading its risk control and compliance affairs.

Leo has over 20 years of experience in risk control and compliance. Prior to joining Huaige Capital, he was co-founder and head of risk control and compliance at Hongyi Investment where he also was assigned representative of the managing partner at Hongyi Boxin and Hongyi Borui.

Leo holds B.B.A from South China Normal University

Steve Fang is a Partner of Huaige Capital and leading its investment banking operations. Steve sits on the board of Cofoe medical and Bestudy.

Steve has over 10 years working experience in auditing, investment banking and legal advisory. Prior to joining Huaige Capital, Steve was a vice-general manager at Jisheng Investment. Previously, Steve was a project manager at BDO China Shu Lun Pan CPAs.

Steve holds B.B.A from Shanghai Lixin University of Commerce. He is a Chinese Certified Public Accountant(CICPA) and a Chinese Certified Tax Agents(CICTA). Steve also passed China National Judicial Examination and possesses legal profession qualification.

Frank Du is a Partner of Huaige Capital and leading its investments of pharmaceuticals. 

Frank has over 10 years of working experience in drug development and venture investment. He has led investments in Biosense, Leads Biolabs, Leto Laboratories, Resproly, ZYAK, etc., and currently sits on the board of Biosense and Resproly.

Before joining Huaige Capital, Frank was the general manager of Honglei Investment where he led its healthcare investments. Prior to that, he was a study director at Shanghai Drug Metabolism and Pharmacokinetics Center where he had been involved in the preclinical and clinical development of several state category I new drugs, covering fields of anti-tumor and autoimmune diseases.

Frank holds Ph.D. from Shanghai Institute of Materia Medica of Chinese Academy of Sciences(SIMM-CAS) and BSc from China Pharmaceutical University.

Thomas Yang is a director of Huaige Capital and leading its investments of medical devices.

Thomas has over 10 years of working experience in academia and private equity investment. His investment portfolio includes YHLO, Nycristetc,etc.

Before joining Huaige Capital, Thomas was an investment director at KCH Capital. Prior to that, he was an associate director at China Science & Merchants Capital. Thomas began his career as an associate research fellow at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences(SIAT-CAS). His academic work has been widely reported by the American chemical society, the Royal Society of Chemistry, the American Physical Union, Springer, and Elsevier, etc.

Thomas holds Ph.D. from the Technical Institute of Physics and Chemistry of the Chinese Academy of Sciences (TIPC-CAS).